株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

不眠症治療の世界市場:成長、動向、および予測

Insomnia Treatment Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 704962
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
不眠症治療の世界市場:成長、動向、および予測 Insomnia Treatment Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年09月01日 ページ情報: 英文 114 Pages
概要

当レポートは世界の不眠症治療市場について調査しており、市場機会や課題、成長および阻害要因、治療タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 治療タイプ別
    • ベンゾジアゼピン
    • ノンベンゾジアゼピン
    • 抗うつ薬
    • オレキシン拮抗薬
    • メラトニン拮抗薬
    • その他
  • 流通チャネル別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Merck & Co.
    • Mylan N.V.
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • 大日本住友製薬株式会社
    • 武田薬品工業株式会社
    • Teva Pharmaceutical Industries Ltd.
    • Vanda Pharmaceuticals Inc.

第7章 市場機会および将来動向

目次
Product Code: 62832

Market Overview

In a study published in PMC in 2015 by "Hindawi Journal" (by Timothy Fitzgerald and Jeffrey Vietri), it was revealed that approximately 25% of US adults have conveyed discontent regarding their sleep, of which 10 to 15% claim to experienced insomnia symptoms and 6-10% suffer from insomnia. The study also shows that approximately 70% of patients suffering from partial stages of insomnia also end up reporting insomnia disorder within one year, and 50% of that population continues to suffer from the symptoms for the next three years. The study suggests that insomnia has become one of the most prevalent disorders being reported in the primary care setup. Also, a high comorbidity rate has been observed between insomnia and medical or some psychiatric disorders. These statistics are a direct consequence of the increasing stress due to the current lifestyle of the urban population.

The other factors such as side effects due to certain OTC and prescription medication, arthritis, high usage of media devices before sleep, are driving the number of people suffering from insomnia, thus boosting the market growth prospects. Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period.

Scope of the Report

As per the scope of the report, Insomnia is a sleep disorder, which has one or more symptoms of fatigue, inability to focus or concentrate, poor memory, mood disturbance, daytime sleepiness, and low motivation or energy. According to the American Psychiatric Association (APA) approximately one-third of the adults suffer from insomnia during their lifetime.

Key Market Trends

Orexin Antagonist segment is expected to grow in the forecast period

The global insomnia treatment market is segmented based on treatment type, which includes benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonist, melatonin antagonist, and other treatment types. The distribution channel includes hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.

The insomnia drugs comprise of a wide range of patented drugs, as well as generics. The patented drugs hold a larger share in developed regions, owing to the better reimbursement policies. The orexin antagonist segment is expected to grow rapidly during the forecast period due to its greater efficacy than other drugs.

North America is expected to dominate the Insomnia Treatment market

North America leads the insomnia treatment market. The growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market over the forecast period. Along with this, the rise in awareness and high health care spending are also expected to drive the market. Other factors that will promote the demand for insomnia drugs includes rapidly growing geriatric population and rising prevalence of sleep disorders and stress.

Competitive Landscape

The insomnia treatment market is fragmented in nature owing to the presence of multiple generic manufacturers. A few players operating in the market offer branded drugs options, however, price sensitivity is an issue in several emerging regions. Additionally, major manufacturers are focusing on the development of new molecules to gain a competitive edge and tap the high unmet needs in the market. The major players in the market are Merck & Co., Mylan N.V., Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Constantly Increasing Noise Levels in the Urban Areas
    • 4.2.2 Increasing Stress Due to Highly Active Lifestyle of Individuals
    • 4.2.3 Side Effects Due to Certain OTC and Prescription Medication
    • 4.2.4 Arthritis, and Back pain Hindering Sleep
    • 4.2.5 High Usage of Media Devices before Sleep
  • 4.3 Market Restraints
    • 4.3.1 Misconceptions about the Seriousness of Insomnia
    • 4.3.2 Patient Non-Adherence due to Characteristic Side Effects of Insomnia Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Benzodiazepines
    • 5.1.2 Nonbenzodiazepines
    • 5.1.3 Antidepressants
    • 5.1.4 Orexin Antagonist
    • 5.1.5 Melatonin Antagonist
    • 5.1.6 Other Treatment
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies and Drug Stores
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co.
    • 6.1.2 Mylan N.V.
    • 6.1.3 Paratek Pharmaceuticals, Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Sanofi S.A.
    • 6.1.6 Sumitomo Dainippon Pharma Co., Ltd.
    • 6.1.7 Takeda Pharmaceutical Company Ltd.
    • 6.1.8 Teva Pharmaceutical Industries Ltd.
    • 6.1.9 Vanda Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top